Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to offer subjects from centers in Taiwan who successfully
complete 168 weeks of treatment in study GS US 174-0108 access to treatment with tenofovir DF
for up to three additional years (144 weeks). Subjects will be followed per local standard of
care. Serious adverse events (SAEs), drug accountability and patient disposition will be
recorded.